These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11436961)

  • 1. Myoclonus during prolonged treatment with sertraline in an adolescent patient.
    Ghaziuddin N; Iqbal A; Khetarpal S
    J Child Adolesc Psychopharmacol; 2001; 11(2):199-202. PubMed ID: 11436961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Zarinara AR; Mohammadi MR; Hazrati N; Tabrizi M; Rezazadeh SA; Rezaie F; Akhondzadeh S
    Hum Psychopharmacol; 2010 Nov; 25(7-8):530-5. PubMed ID: 20860068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seizures associated with venlafaxine, methylphenidate, and zolpidem.
    Tavakoli SA; Gleason OC
    Psychosomatics; 2003; 44(3):262-4. PubMed ID: 12724513
    [No Abstract]   [Full Text] [Related]  

  • 4. Methylphenidate-induced acute orofacial and extremity dyskinesia.
    Yilmaz AE; Donmez A; Orun E; Tas T; Isik B; Sonmez FM
    J Child Neurol; 2013 Jun; 28(6):781-3. PubMed ID: 22791547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute focal dystonic reaction after acute methylphenidate treatment in an adolescent patient.
    Tekin U; Soyata AZ; Oflaz S
    J Clin Psychopharmacol; 2015 Apr; 35(2):209-11. PubMed ID: 25607477
    [No Abstract]   [Full Text] [Related]  

  • 6. Methylphenidate euphoria.
    Corrigall R; Ford T
    J Am Acad Child Adolesc Psychiatry; 1996 Nov; 35(11):1421. PubMed ID: 8936903
    [No Abstract]   [Full Text] [Related]  

  • 7. Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study.
    Di Martino A; Melis G; Cianchetti C; Zuddas A
    J Child Adolesc Psychopharmacol; 2004; 14(2):207-18. PubMed ID: 15319018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
    Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1149-50; author reply 1151-2. PubMed ID: 17493730
    [No Abstract]   [Full Text] [Related]  

  • 9. Methylphenidate (Ritalin) use and abuse.
    Crutchley A; Temlett JA
    S Afr Med J; 1999 Oct; 89(10):1076-9. PubMed ID: 10582063
    [No Abstract]   [Full Text] [Related]  

  • 10. Central stimulants in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. A naturalistic study of the prescription in Sweden, 1977-2007.
    Janols LO; Liliemark J; Klintberg K; von Knorring AL
    Nord J Psychiatry; 2009 Nov; 63(6):508-16. PubMed ID: 19958258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication-induced seizures.
    Feeney DJ; Klykylo WM
    J Am Acad Child Adolesc Psychiatry; 1997 Aug; 36(8):1018-9. PubMed ID: 9256580
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of hyperactivity in children with pervasive developmental disorders.
    Scahill L; Pachler M
    J Child Adolesc Psychiatr Nurs; 2007 Feb; 20(1):59-62. PubMed ID: 17284238
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury.
    Lee H; Kim SW; Kim JM; Shin IS; Yang SJ; Yoon JS
    Hum Psychopharmacol; 2005 Mar; 20(2):97-104. PubMed ID: 15641125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The run on Ritalin. Attention deficit disorder and stimulant treatment in the 1990s.
    Diller LH
    Hastings Cent Rep; 1996; 26(2):12-8. PubMed ID: 8722521
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylphenidate-Associated Onychotillomania, Myoclonus, and Enuresis Reversed by Switching to Atomoxetine.
    Naguy A; Alamiri B; El-Sori DS; Khraibut B
    Am J Ther; 2019; 26(5):e614-e616. PubMed ID: 29927775
    [No Abstract]   [Full Text] [Related]  

  • 18. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
    Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone-to-methylphenidate switch reaction in children: three cases.
    Sabuncuoglu O
    J Psychopharmacol; 2007 Mar; 21(2):216-9. PubMed ID: 17329303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.